Switching anti-TNF-α agents: What is the evidence?

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The availability of biologic agents targeting tumor necrosis factor (TNF)-α represents a significant advance in the management of rheumatoid arthritis. Anti-TNF-α therapy has been associated with dramatic improvements in the clinical signs and symptoms of rheumatoid arthritis and has been shown to greatly retard the destructive process that too often characterizes this condition. Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been well described, affecting up to one-third to one-half of subjects treated with these agents. Switching from one anti-TNF-α agent to a second (or even third) anti-TNF-α therapy has emerged as a means of addressing treatment failures with this drug class. This review examines data addressing the practice of switching anti-TNF-α agents in the context of initial treatment failure, with a focus on data from peer-reviewed reports.

Original languageEnglish (US)
Pages (from-to)416-420
Number of pages5
JournalCurrent rheumatology reports
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2007

Fingerprint

Tumor Necrosis Factor-alpha
Treatment Failure
Rheumatoid Arthritis
Biological Factors
Signs and Symptoms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Switching anti-TNF-α agents : What is the evidence? / Erickson, Alan R; Mikuls, Ted R.

In: Current rheumatology reports, Vol. 9, No. 5, 01.10.2007, p. 416-420.

Research output: Contribution to journalReview article

@article{5082f4d5f0dc486390da940cdba75f5a,
title = "Switching anti-TNF-α agents: What is the evidence?",
abstract = "The availability of biologic agents targeting tumor necrosis factor (TNF)-α represents a significant advance in the management of rheumatoid arthritis. Anti-TNF-α therapy has been associated with dramatic improvements in the clinical signs and symptoms of rheumatoid arthritis and has been shown to greatly retard the destructive process that too often characterizes this condition. Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been well described, affecting up to one-third to one-half of subjects treated with these agents. Switching from one anti-TNF-α agent to a second (or even third) anti-TNF-α therapy has emerged as a means of addressing treatment failures with this drug class. This review examines data addressing the practice of switching anti-TNF-α agents in the context of initial treatment failure, with a focus on data from peer-reviewed reports.",
author = "Erickson, {Alan R} and Mikuls, {Ted R}",
year = "2007",
month = "10",
day = "1",
doi = "10.1007/s11926-007-0066-2",
language = "English (US)",
volume = "9",
pages = "416--420",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Switching anti-TNF-α agents

T2 - What is the evidence?

AU - Erickson, Alan R

AU - Mikuls, Ted R

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The availability of biologic agents targeting tumor necrosis factor (TNF)-α represents a significant advance in the management of rheumatoid arthritis. Anti-TNF-α therapy has been associated with dramatic improvements in the clinical signs and symptoms of rheumatoid arthritis and has been shown to greatly retard the destructive process that too often characterizes this condition. Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been well described, affecting up to one-third to one-half of subjects treated with these agents. Switching from one anti-TNF-α agent to a second (or even third) anti-TNF-α therapy has emerged as a means of addressing treatment failures with this drug class. This review examines data addressing the practice of switching anti-TNF-α agents in the context of initial treatment failure, with a focus on data from peer-reviewed reports.

AB - The availability of biologic agents targeting tumor necrosis factor (TNF)-α represents a significant advance in the management of rheumatoid arthritis. Anti-TNF-α therapy has been associated with dramatic improvements in the clinical signs and symptoms of rheumatoid arthritis and has been shown to greatly retard the destructive process that too often characterizes this condition. Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been well described, affecting up to one-third to one-half of subjects treated with these agents. Switching from one anti-TNF-α agent to a second (or even third) anti-TNF-α therapy has emerged as a means of addressing treatment failures with this drug class. This review examines data addressing the practice of switching anti-TNF-α agents in the context of initial treatment failure, with a focus on data from peer-reviewed reports.

UR - http://www.scopus.com/inward/record.url?scp=35348984613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348984613&partnerID=8YFLogxK

U2 - 10.1007/s11926-007-0066-2

DO - 10.1007/s11926-007-0066-2

M3 - Review article

C2 - 17915098

AN - SCOPUS:35348984613

VL - 9

SP - 416

EP - 420

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 5

ER -